Posted inBiotechnology
BMS-backed Beeline ‘putting worker bee mentality into effect’ with $126M series A extension
Just two and a half months after buzzing out of stealth with $300 million and five autoimmune programs from Bristol…
Posted inGenetics
CCRM Ireland Would Be Established to Hasten Translation of Advanced Therapies Into Patient Treatments
Credit: CCRM Rinn Advanced Therapies, Ireland’s national research center for personalized immune cell therapies, signed a Memorandum of Understanding (MOU)…
Posted inGenetics
Tecan Integrates Agentic AI Into Its Introspect Lab Analytics Platform
Credit: WUT789/Getty Images Tecan reported the integration of agentic AI capabilities into its lab analytics platform Introspect, leveraging the NVIDIA…
Posted inBiotechnology
BioCryst ends internal discovery programs, closes Alabama facility in pivot to cost-saving partnerships
After scrapping development of its diabetic macular edema treatment avoralstat last month, BioCryst Pharmaceuticals is shuttering all internal discovery programs…
Posted inBiotechnology
Evommune’s phase 2b trial flops, ending challenge to Novartis in hives
A phase 2b trial of Evommune’s EVO756 has missed its primary endpoint, wiping out a would-be rival to Novartis for the…
Posted inMedical Technology
Production problems hamper Lantheus bid for FDA approval of radiopharma dx kit
The FDA dealt Lantheus’ bid to garner approval of its radiodiopharmaceutical diagnostic kit a setback due to manufacturing issues at…
Posted inBiotechnology
UK-based Scancell bids to buy Nasdaq-listed Neuphoria to ‘increase profile’ with US investors
As Neuphoria Therapeutics continues to navigate the fallout of its failed social anxiety program, the biotech is mulling an offer…
Posted inMedical Technology
Roche launches Axelios 1, its eagerly awaited gene sequencing rival to Illumina
Roche may have failed to buy out Illumina back in 2012, but now it’s trying to take up some of…
Posted inMedical Technology
United Therapeutics nabs FDA approval for donor-lung assessment device
United Therapeutics has been given a premarket approval (PMA) from the FDA for its LungFX device. The product can now…
Posted inBiotechnology
AstraZeneca unveils phase 3 bone disease data behind $5B forecast for Strensiq successor
AstraZeneca has shared the data behind previously disclosed phase 3 rare disease wins, fleshing out the case for a Strensiq successor…